Buntanetap |
ANVS-405; ANVS-401 |
Phase 3 Clinical |
Raptor Pharmaceutical |
Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Florzolotau (Aprinoia Therapeutics) |
[18F]APN-1607; [18F]MNI-958; APN-0000455; F0-PBB3; PM-PBB3; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607 |
Phase 3 Clinical |
Aprinoia Therapeutics Ltd |
Supranuclear Palsy, Progressive; Nerve Degeneration; Alzheimer Disease; Cognitive Dysfunction; Diagnostic agents; Cognition Disorders |
Details
|
E-2814 |
E-2814 |
Phase 3 Clinical |
Eisai Co Ltd |
Dementia; Alzheimer Disease |
Details
|
Izaflortaucipir F-18 |
[18F]PI-2620; PI-2620; 18F-PI-2620 |
Phase 3 Clinical |
Piramal, Ac Immune Sa |
Hypotension; Supranuclear Palsy, Progressive; Brain Concussion; Opioid-Related Disorders; Frontotemporal Lobar Degeneration; Alzheimer Disease; Cognitive Dysfunction |
Details
|
Leuco methylthioninium |
LMT-X; TRX-0237; Leuco-MTx; LMTM; L-MTx; HMTM |
Phase 3 Clinical |
Taurx Pharmaceuticals |
Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Zagotenemab |
LY-3303560 |
Phase 2 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
Posdinemab |
JNJ-63733657; JNJ-3657 |
Phase 2 Clinical |
Johnson & Johnson Innovative Medicine |
Alzheimer Disease; Cognitive Dysfunction; Dementia |
Details
|
[18F]GTP-1 |
[18F]GTP-1 |
Phase 2 Clinical |
Genentech Inc |
Alzheimer Disease |
Details
|
FluoroTau |
[18F]THK-5351; GE-216; F-18-THK-5351 |
Phase 2 Clinical |
Tohoku University |
Kidney Neoplasms; Carcinoma, Renal Cell; Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Diabetes Mellitus |
Details
|
[18F]THK-5105 |
[18F]THK-5105 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
ISIS-814907 |
BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX |
Phase 2 Clinical |
Biogen Inc, Ionis Pharmaceuticals Inc |
Cognitive Dysfunction; Dementia; Alzheimer Disease |
Details
|
Tilavonemab |
C2N-8E12; ABBV-8E12 |
Phase 2 Clinical |
C2n Diagnostics Llc |
Supranuclear Palsy, Progressive; Alzheimer Disease |
Details
|
Alzheimer's disease vaccine (Axon Neuroscience) |
AADvac-1 |
Phase 2 Clinical |
Axon Biochemicals |
Alzheimer Disease; Primary Progressive Nonfluent Aphasia |
Details
|
Semorinemab |
MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 |
Phase 2 Clinical |
Ac Immune Sa |
Alzheimer Disease |
Details
|
APN-1701 |
[18F]AM-PBB3; 18F-AM-PBB3; APN-1701 |
Phase 2 Clinical |
National Institute Of Radiological Sciences, Aprinoia Therapeutics Ltd |
Nerve Degeneration; Alzheimer Disease |
Details
|
Anti-tau antibody (Prothena) |
PRX-005; BMS-986446 |
Phase 2 Clinical |
Prothena |
Alzheimer Disease; Frontotemporal Dementia |
Details
|
Bepranemab |
UCB-0107 |
Phase 2 Clinical |
Ucb |
Supranuclear Palsy, Progressive; Alzheimer Disease |
Details
|
[18F]THK-5117 |
[18F]THK-5117 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
ASN-120290 |
ASN-561; ASN-90; ASN-120290 |
Phase 1 Clinical |
Merck Serono |
Alzheimer Disease; Parkinson Disease |
Details
|
PNT-001 |
PNT-001 |
Phase 1 Clinical |
Pinteon Therapeutics Inc |
Brain Injuries, Traumatic; Alzheimer Disease |
Details
|
ReS19-T |
ReS19-T |
Phase 1 Clinical |
Remynd |
Alzheimer Disease |
Details
|
Mecripyrine Hydrochloride |
SCR-1693; Y-1A; Y-1 |
Phase 1 Clinical |
Jiangsu Simcere Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd, NeuroDawn Pharmaceutical Co Ltd |
Brain Neoplasms; Alzheimer Disease |
Details
|
Lu-AF87908 |
Lu-AF87908; Lu-AF-87908 |
Phase 1 Clinical |
H. Lundbeck A/S |
Alzheimer Disease |
Details
|
RDC-5 |
RDC-5 |
Phase 1 Clinical |
Chronos Therapeutics Ltd |
Amyotrophic Lateral Sclerosis |
Details
|
MC-1 (Lilly) |
MC-1 (Lilly) |
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
OLX-07010 |
OLX07010 |
Phase 1 Clinical |
Oligomerix Inc |
Supranuclear Palsy, Progressive; Alzheimer Disease; Dementia; Neurodegenerative Diseases |
Details
|
Protollin |
|
Phase 1 Clinical |
Brigham and Women's Hospital Inc |
Alzheimer Disease |
Details
|
ADEL-Y01 |
ADEL-Y01 |
Phase 1 Clinical |
Oscotec Inc, ADEL Inc |
Tauopathies; Alzheimer Disease |
Details
|
MK-2214 |
MK-2214 |
Phase 1 Clinical |
Merck Sharp & Dohme LLC |
Alzheimer Disease |
Details
|
APNmAb-005 |
APNmAb-005 |
Phase 1 Clinical |
Aprinoia Therapeutics Ltd |
Nerve Degeneration; Alzheimer Disease; Tauopathies |
Details
|
XTR-006 |
XTR-006 |
Phase 1 Clinical |
|
Tauopathies; Alzheimer Disease |
Details
|
NIO-752 |
NIO-752 |
Phase 1 Clinical |
Novartis Pharma Ag |
Supranuclear Palsy, Progressive; Cognitive Dysfunction; Alzheimer Disease; Neurodegenerative Diseases |
Details
|
BEY-2153 |
BEY-2153 |
Phase 1 Clinical |
Beyondbio Inc |
Alzheimer Disease |
Details
|
BIIB-076 |
NI-105; BIIB-076 |
Phase 1 Clinical |
Biogen Inc, Neurimmune Ag |
Alzheimer Disease |
Details
|
11C-PBB3 |
11C-PBB3 |
Clinical |
National Institute Of Radiological Sciences |
Alzheimer Disease |
Details
|
Buntanetap |
ANVS-405; ANVS-401 |
Phase 3 Clinical |
Raptor Pharmaceutical |
Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Florzolotau (Aprinoia Therapeutics) |
[18F]APN-1607; [18F]MNI-958; APN-0000455; F0-PBB3; PM-PBB3; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607 |
Phase 3 Clinical |
Aprinoia Therapeutics Ltd |
Supranuclear Palsy, Progressive; Nerve Degeneration; Alzheimer Disease; Cognitive Dysfunction; Diagnostic agents; Cognition Disorders |
Details
|
E-2814 |
E-2814 |
Phase 3 Clinical |
Eisai Co Ltd |
Dementia; Alzheimer Disease |
Details
|
Izaflortaucipir F-18 |
[18F]PI-2620; PI-2620; 18F-PI-2620 |
Phase 3 Clinical |
Piramal, Ac Immune Sa |
Hypotension; Supranuclear Palsy, Progressive; Brain Concussion; Opioid-Related Disorders; Frontotemporal Lobar Degeneration; Alzheimer Disease; Cognitive Dysfunction |
Details
|
Leuco methylthioninium |
LMT-X; TRX-0237; Leuco-MTx; LMTM; L-MTx; HMTM |
Phase 3 Clinical |
Taurx Pharmaceuticals |
Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia |
Details
|
Zagotenemab |
LY-3303560 |
Phase 2 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
Posdinemab |
JNJ-63733657; JNJ-3657 |
Phase 2 Clinical |
Johnson & Johnson Innovative Medicine |
Alzheimer Disease; Cognitive Dysfunction; Dementia |
Details
|
[18F]GTP-1 |
[18F]GTP-1 |
Phase 2 Clinical |
Genentech Inc |
Alzheimer Disease |
Details
|
FluoroTau |
[18F]THK-5351; GE-216; F-18-THK-5351 |
Phase 2 Clinical |
Tohoku University |
Kidney Neoplasms; Carcinoma, Renal Cell; Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Diabetes Mellitus |
Details
|
[18F]THK-5105 |
[18F]THK-5105 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
ISIS-814907 |
BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX |
Phase 2 Clinical |
Biogen Inc, Ionis Pharmaceuticals Inc |
Cognitive Dysfunction; Dementia; Alzheimer Disease |
Details
|
Tilavonemab |
C2N-8E12; ABBV-8E12 |
Phase 2 Clinical |
C2n Diagnostics Llc |
Supranuclear Palsy, Progressive; Alzheimer Disease |
Details
|
Alzheimer's disease vaccine (Axon Neuroscience) |
AADvac-1 |
Phase 2 Clinical |
Axon Biochemicals |
Alzheimer Disease; Primary Progressive Nonfluent Aphasia |
Details
|
Semorinemab |
MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 |
Phase 2 Clinical |
Ac Immune Sa |
Alzheimer Disease |
Details
|
APN-1701 |
[18F]AM-PBB3; 18F-AM-PBB3; APN-1701 |
Phase 2 Clinical |
National Institute Of Radiological Sciences, Aprinoia Therapeutics Ltd |
Nerve Degeneration; Alzheimer Disease |
Details
|
Anti-tau antibody (Prothena) |
PRX-005; BMS-986446 |
Phase 2 Clinical |
Prothena |
Alzheimer Disease; Frontotemporal Dementia |
Details
|
Bepranemab |
UCB-0107 |
Phase 2 Clinical |
Ucb |
Supranuclear Palsy, Progressive; Alzheimer Disease |
Details
|
[18F]THK-5117 |
[18F]THK-5117 |
Phase 2 Clinical |
Tohoku University |
Alzheimer Disease |
Details
|
ASN-120290 |
ASN-561; ASN-90; ASN-120290 |
Phase 1 Clinical |
Merck Serono |
Alzheimer Disease; Parkinson Disease |
Details
|
PNT-001 |
PNT-001 |
Phase 1 Clinical |
Pinteon Therapeutics Inc |
Brain Injuries, Traumatic; Alzheimer Disease |
Details
|
ReS19-T |
ReS19-T |
Phase 1 Clinical |
Remynd |
Alzheimer Disease |
Details
|
Mecripyrine Hydrochloride |
SCR-1693; Y-1A; Y-1 |
Phase 1 Clinical |
Jiangsu Simcere Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd, NeuroDawn Pharmaceutical Co Ltd |
Brain Neoplasms; Alzheimer Disease |
Details
|
Lu-AF87908 |
Lu-AF87908; Lu-AF-87908 |
Phase 1 Clinical |
H. Lundbeck A/S |
Alzheimer Disease |
Details
|
RDC-5 |
RDC-5 |
Phase 1 Clinical |
Chronos Therapeutics Ltd |
Amyotrophic Lateral Sclerosis |
Details
|
MC-1 (Lilly) |
MC-1 (Lilly) |
Phase 1 Clinical |
Eli Lilly And Company |
Alzheimer Disease |
Details
|
OLX-07010 |
OLX07010 |
Phase 1 Clinical |
Oligomerix Inc |
Supranuclear Palsy, Progressive; Alzheimer Disease; Dementia; Neurodegenerative Diseases |
Details
|
Protollin |
|
Phase 1 Clinical |
Brigham and Women's Hospital Inc |
Alzheimer Disease |
Details
|
ADEL-Y01 |
ADEL-Y01 |
Phase 1 Clinical |
Oscotec Inc, ADEL Inc |
Tauopathies; Alzheimer Disease |
Details
|
MK-2214 |
MK-2214 |
Phase 1 Clinical |
Merck Sharp & Dohme LLC |
Alzheimer Disease |
Details
|
APNmAb-005 |
APNmAb-005 |
Phase 1 Clinical |
Aprinoia Therapeutics Ltd |
Nerve Degeneration; Alzheimer Disease; Tauopathies |
Details
|
XTR-006 |
XTR-006 |
Phase 1 Clinical |
|
Tauopathies; Alzheimer Disease |
Details
|
NIO-752 |
NIO-752 |
Phase 1 Clinical |
Novartis Pharma Ag |
Supranuclear Palsy, Progressive; Cognitive Dysfunction; Alzheimer Disease; Neurodegenerative Diseases |
Details
|
BEY-2153 |
BEY-2153 |
Phase 1 Clinical |
Beyondbio Inc |
Alzheimer Disease |
Details
|
BIIB-076 |
NI-105; BIIB-076 |
Phase 1 Clinical |
Biogen Inc, Neurimmune Ag |
Alzheimer Disease |
Details
|
11C-PBB3 |
11C-PBB3 |
Clinical |
National Institute Of Radiological Sciences |
Alzheimer Disease |
Details
|